With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a bigger player in oncology. Sales for bladder cancer drug Padcev, lung cancer ...

Pfizer Inc. just made headlines by acquiring a promising biotech firm. The strategic move aims to enhance Pfizer's portfolio ...

Pfizer's stock rose 8.03%, despite bearish technicals and mixed analyst ratings. Technical indicators signal a bearish ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...

Pfizer Inc. (NYSE:PFE) is one of the top cheap pharmaceutical stocks to buy now. On June 25, Pfizer Inc. (NYSE:PFE) announced ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...